Abstract
Purpose
To evaluate the relationships between baseline visual field (VF) mean deviation (MD) and subsequent progression in treated glaucoma.
Methods
Records of patients seen in a glaucoma practice between 1999 and 2009 were reviewed. Patients with glaucomatous optic neuropathy, baseline VF damage, and ≥8 SITA-standard 24-2 VF were included. Patients were divided into tertiles based upon baseline MD. Automated pointwise linear regression determined global and localized rates (decibels (dB) per year) of change. Progression was defined when two or more adjacent test locations in the same hemifield showed a sensitivity decline at a rate of >1.0 dB per year, P<0.01.
Results
For mild, moderate, and severe groups, progression was noted in 29.5, 31.2, and 26.0% of eyes (P=0.50) and global rates of VF change of progressing eyes were −1.3±1.2, −1.01±0.7, and −0.9±0.5 dB/year (P=0.09, analysis of variance). Within these groups, intraocular pressure (IOP) in stable vs progressing eyes were 15.5±3.3 vs 17.0±3.1 (P<0.01), 15.4±3.3 vs 15.9±2.5 (P=0.28), and 14.0±2.8 vs 14.8±2.3 mm Hg (P=0.07). More glaucoma filtering surgeries were performed in eyes with worse MD. There was no significant difference between groups regarding their risk of progression in both univariate (P=0.50) and multivariate (P=0.26) analyses adjusting for differences in follow-up IOP.
Conclusions
After correcting for differences in IOP in treated glaucoma patients, we did not find a relationship between the rate of VF change (dB per year) and the severity of the baseline VF MD. This finding may have been due to more aggressive IOP lowering in eyes with more severe disease. Eyes with lower IOP progressed less frequently across the spectrum of VF loss.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701–713.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M . Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120: 1268–1279.
AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 490–491.
Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA et al. CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108: 1943–1953.
Miglior S, Torri V, Zeyen T, Pfeiffer N, Vaz JC, Adamsons I . Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. Am J Ophthalmol 2007; 144 (2): 266–275.
Medeiros FA, Sample PA, Zangwill LM, Bowd C, Aihara M, Weinreb RN . Corneal thickness as a risk factor for visual field loss in patients with preperimetric glaucomatous optic neuropathy. Am J Ophthalmol 2003; 136: 805–813.
Drance S, Anderson DR, Schulzer M . Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001; 131: 699–708.
Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z, EMGT Group. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114: 1965–1972.
Nouri-Mahdavi K, Hoffman D, Gaasterland D, Caprioli J . Prediction of visual field progression in glaucoma. Invest Ophthalmol Vis Sci 2004; 45: 4346–4351.
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 714–720.
Cioffi GA, Liebmann JM . Translating the OHTS results into clinical practice. J Glaucoma 2002; 11: 375–377.
Singh K . The randomized clinical trial: beware of limitations. J Glaucoma 2004; 13: 87–89.
Jampel HD . We should treat fewer patients with elevated intraocular pressure now that we know the results of the Ocular Hypertension Treatment Study. Arch Ophthalmol 2004; 122: 378–379.
Wishart PK . Interpretation of the glaucoma ‘landmark studies’. Br J Ophthalmol 2009; 93: 561–562.
Kass MA, Gordon MO, Kymes SM . Incorporating the results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol 2005; 123: 1021–1022.
Kent DM, Kitsios G . Against pragmatism: on efficacy, effectiveness and the real world. Trials 2009; 10: 48.
Tunis SR, Stryer DB, Clancy CM . Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624–1632.
Glasgow RE, Magid DJ, Beck A, Ritzwoller D, Estabrooks PA . Practical clinical trials for translating research to practice: design and measurement recommendations. Med Care 2005; 43: 551–557.
De Moraes CG, Ritch R, Liebmann JM . Bridging the major prospective National Eye Institute-sponsored glaucoma clinical trials and clinical practice. J Glaucoma 2011; 20: 1–2.
Chauhan BC, Garway-Heath DF, Goñi FJ, Rossetti L, Bengtsson B, Viswanathan AC et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008; 92 (4): 569–573.
Spry PG, Bates AB, Johnson CA, Chauhan BC . Simulation of longitudinal threshold visual field data. Invest Ophthalmol Vis Sci 2000; 41 (8): 2192–2200.
De Moraes CG, Juthani V, Liebmann JM, Teng CC, Tello C, Susanna R et al. Risk factors for visual field progression in treated glaucoma. Arch Ophthalmol 2010 (in press).
Fitzke FW, Hitchings RA, Poinoosawmy D, McNaught AI, Crabb DP . Analysis of visual field progression in glaucoma. Br J Ophthalmol 1996; 80: 40–48.
Gardiner SK, Crabb DP . Examination of different pointwise linear regression methods for determining visual field progression. Invest Ophthalmol Vis Sci 2002; 43: 1400–1407.
McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP, Los Angeles Latino Eye Study Group. Severity of visual field loss and health-related quality of life. Am J Ophthalmol 2007; 143: 1013–1023.
De Moraes CG, Prata TS, Tello C, Ritch R, Liebmann JM . Glaucoma with early visual field loss affecting both hemifields and the risk of disease progression. Arch Ophthalmol 2009; 127: 1129–1134.
Quigley HA, Dunkelberger GR, Green WR . Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 1989; 107: 453–464.
Acknowledgements
This study was supported in part by the Irvin Kessler Research Fund of the New York Glaucoma Research Institute, New York, NY, USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
This material was presented as a poster at ARVO 2010.
Rights and permissions
About this article
Cite this article
Forchheimer, I., de Moraes, C., Teng, C. et al. Baseline mean deviation and rates of visual field change in treated glaucoma patients. Eye 25, 626–632 (2011). https://doi.org/10.1038/eye.2011.33
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2011.33
Keywords
This article is cited by
-
Persistent severe visual field impairment is associated with obesity and tumour invasiveness, but not with pituitary dysfunction, in patients with craniopharyngioma
Endocrine (2023)
-
Association of macular structure, function, and vessel density with foveal threshold in advanced glaucoma
Scientific Reports (2022)
-
Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population
International Ophthalmology (2022)
-
Long-term treatment success and safety of combined phacoemulsification plus excimer laser trabeculostomy: an 8-year follow-up study
Graefe's Archive for Clinical and Experimental Ophthalmology (2022)
-
Visual field progression in patients with severe glaucoma
Graefe's Archive for Clinical and Experimental Ophthalmology (2021)
